Literature DB >> 2197338

Monoclonal antibody to endotoxin core protects mice from Escherichia coli sepsis by a mechanism independent of tumor necrosis factor and interleukin-6.

A T Silva1, B J Appelmelk, W A Buurman, K F Bayston, J Cohen.   

Abstract

To study the role of cytokines as mediators of endotoxin-induced shock, the serum levels of tumor necrosis factor (TNF) and interleukin-6 (IL-6) were compared in mice receiving either a monoclonal antibody to endotoxin core (clone 20), an irrelevant monoclonal antibody (A1), or culture media (DMEM/FCS) alone before lethal challenge with live Escherichia coli O111:B4. Clone 20 given 1.5 h before the bacterial challenge protected mice from death (mortality at 48 h 3% vs. 87%, P less than .001). The pattern of IL-6 release was indistinguishable in clone 20 recipients and controls: The area under the curve (AUC) for 5 h was 1.22 +/- 0.07 x 10(6), 1.03 +/- 0.17 x 10(6), and 1.22 +/- 0.07 x 10(6) units/ml for clone 20, A1, and DMEM/FCS, respectively. Similarly, the timing and extent of TNF release in the serum was virtually identical in clone 20 recipients that survived and control animals that died. AUC for 5 h was 30.8 +/- 4.0 x 10(3), 28.1 +/- 1.1 x 10(3), and 30.4 +/- 4.7 x 10(3) ng/ml in clone 20, A1, and DMEM/FCS recipients, respectively. Thus, TNF and IL-6 appear insufficient to cause death in this model of experimental gram-negative shock.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2197338     DOI: 10.1093/infdis/162.2.454

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Endotoxaemia and serum tumour necrosis factor as prognostic markers in severe acute pancreatitis.

Authors:  A R Exley; T Leese; M P Holliday; R A Swann; J Cohen
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

2.  Do streptococci cause toxic shock?

Authors:  J Cohen; K Bayston; M Tomlinson
Journal:  BMJ       Date:  1990-12-01

3.  Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates.

Authors:  A F Verheul; G J Boons; G A Van der Marel; J H Van Boom; H J Jennings; H Snippe; J Verhoef; P Hoogerhout; J T Poolman
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

4.  A synthetic lipopolysaccharide-binding peptide based on the neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats.

Authors:  D J Brackett; M R Lerner; M A Lacquement; R He; H A Pereira
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

Review 5.  Immunotherapy in the management of sepsis.

Authors:  E A Fagan; M Singer
Journal:  Postgrad Med J       Date:  1995-02       Impact factor: 2.401

6.  Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats.

Authors:  H Jin; R Yang; S Marsters; A Ashkenazi; S Bunting; M N Marra; R W Scott; J B Baker
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Differential effects of monoclonal antibodies to tumor necrosis factor alpha and gamma interferon on induction of hepatic nitric oxide synthase in experimental gram-negative sepsis.

Authors:  T Evans; A Carpenter; A Silva; J Cohen
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

8.  Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis.

Authors:  S M Opal; A S Cross; J C Sadoff; H H Collins; N M Kelly; G H Victor; J E Palardy; M W Bodmer
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

9.  Inhibition of macrophage-activating cytokines is beneficial in the acute septic response.

Authors:  H P Redmond; K D Chavin; J S Bromberg; J M Daly
Journal:  Ann Surg       Date:  1991-10       Impact factor: 12.969

10.  Inhibition of lipopolysaccharide-associated endotoxin activities in vitro and in vivo by the human anti-lipid A monoclonal antibody SdJ5-1.17.15.

Authors:  I S Fang; M A Wisniewski; C C Huntenburg; L S Knight; J E Bubbers; M J Schneidkraut
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.